Psychopharmacology: A Master Class
Charles Nemeroff, MD, PhD

July 24 – 28, 2017 • Monday – Friday

See Accreditation

REGISTER NOW

This seminar will begin with an updated review of neurobiology and brain. Child abuse and neglect on the brain and how it results in increased vulnerability to mood and anxiety disorders will be explored. An update on the pathophysiology of the major psychiatric disorders will be described including the new data on inflammation.

 

Treatments of schizophrenia, bipolar disorder, depression, anxiety, and women’s disorders will be described. The evidence based effectiveness of antipsychotic medications will be emphasized in psychotic disorders and as augmenting agents in major depression. Newer agents and augmenting medications for the treatment of mood disorders will be discussed with an emphasis on treatment-resistant depression. Bipolar disorder and its treatment will be examined with particular emphasis on bipolar depression. The use of lithium as the gold standard of treatment will be emphasized. A comprehensive review of primary depression as well as depression co-morbid with medical illnesses will be highlighted, particularly the role of depression in cardiovascular illness and the necessity for treatment.

 

The neurobiological mechanisms of anxiety and anxiety-spectrum disorders as well as their treatment will be reviewed, including obsessive-compulsive disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), and generalized anxiety disorder. Medications for depression in women through the course of their lifecycle will be presented.

 

The advances in personalized or precision medicine will be a major focus of the course.

 

The course will emphasize the establishment and importance of therapeutic alliance when prescribing all psychotropic medications.

 

Upon completion of this seminar, participants will be able to:

 

  • Apply the latest advances in the neurobiology of psychiatric disorders and the role of genetic testing in the selection of specific psychiatric medications;
  • Evaluate the effects of neurotransmitters and genes on psychotropic drug treatment;
  • Assess and compare current mechanisms and latest treatment of psychotic disorders, schizophrenia and bipolar illness;
  • Analyze and assess the neurobiological mechanism and evidence-based treatment of depressive and anxiety-spectrum disorders;
  • Review the appropriate use of medications in the treatment of sleep disorders;
  • Review latest findings about inflammation and stress as they apply to the treatment of depressive and anxiety-spectrum disorders;
  • Analyze the role of psychopharmacology in the treatment of generalized anxiety disorder, obsessive symptoms, panic symptoms, and traumatic syndromes;
  • Describe the interaction between psychiatric and medical illnesses;
  • Review the preeminent role of child abuse and neglect on risk for mood and anxiety disorders;
  • Update the clinical approach to problems in geriatric psychopharmacology with emphasis on newly emerging medication treatment;
  • Make dosage adjustments in the elderly for age, drug interactions, and sensitivity to side effects;
  • Review the use of psychiatric medications during a women’s life cycle: pregnancy, delivery, postpartum, nursing, and menopause.

 

SCHEDULE

 

Monday, July 24, 2017

  • An updated and clinically relevant review of neurobiology as it applies to the etiology and pathophysiology of psychiatric illness, and psychotropic drug treatment effects; the neurobiology of child abuse and neglect and implications for the course and treatment of mood and anxiety disorders.
  • Q&A.

 

Tuesday, July 25, 2017

  • Biology and treatment of psychotic disorders including schizophrenia, bipolar illness, psychotic depression, and psychosis associated with neurologic conditions; current standards of practice; special emphasis on evidence-based treatments of bipolar depression.
  • Q&A.

 

Wednesday, July 26, 2017

  • Management of treatment resistant depression with a focus on psychopharmacological treatments; review of STAR*D study and other evidenced based clinical trials.
  • The Burden of Addiction and its treatment including PTSD.
  • Q&A.

 

Thursday, July 27, 2017:

  • Personalized medicine in Psychiatry; diagnosis and treatment of anxiety and anxiety-spectrum disorders; neurobiological mechanisms of anxiety, and the appropriate role of treatments with benzodiazepines, antidepressants, and new approaches.
  • Q&A.

 

Friday, July 28, 2017

  • Mood disorders in women including premenstrual syndrome, pregnancy, lactation, and postpartum depression; presentation of interesting/difficult cases from attendee’s practice for discussion and review.
  • Q&A.